Literature DB >> 26195510

Potential Targets for Antifungal Drug Discovery Based on Growth and Virulence in Candida albicans.

Xiuyun Li1, Yinglong Hou2, Longtao Yue3, Shuyuan Liu1, Juan Du3, Shujuan Sun4.   

Abstract

Fungal infections, especially infections caused by Candida albicans, remain a challenging problem in clinical settings. Despite the development of more-effective antifungal drugs, their application is limited for various reasons. Thus, alternative treatments with drugs aimed at novel targets in C. albicans are needed. Knowledge of growth and virulence in fungal cells is essential not only to understand their pathogenic mechanisms but also to identify potential antifungal targets. This article reviews the current knowledge of the mechanisms of growth and virulence in C. albicans and examines potential targets for the development of new antifungal drugs.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26195510      PMCID: PMC4576120          DOI: 10.1128/AAC.00726-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  94 in total

1.  Mds3 regulates morphogenesis in Candida albicans through the TOR pathway.

Authors:  Lucia F Zacchi; Jonatan Gomez-Raja; Dana A Davis
Journal:  Mol Cell Biol       Date:  2010-05-10       Impact factor: 4.272

2.  TOR regulation: sorting out the answers.

Authors:  Thomas P Neufeld
Journal:  Cell Metab       Date:  2007-01       Impact factor: 27.287

Review 3.  Fungal metabolism in host niches.

Authors:  Matthias Brock
Journal:  Curr Opin Microbiol       Date:  2009-06-15       Impact factor: 7.934

4.  Discrete roles of the Spc1 kinase and the Atf1 transcription factor in the UV response of Schizosaccharomyces pombe.

Authors:  G Degols; P Russell
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

5.  Determination of germ tube, phospholipase, and proteinase production by bloodstream isolates of Candida albicans.

Authors:  Antonella Souza Mattei; Sydney Hartz Alves; Cecília Bittencourt Severo; Luciana da Silva Guazzelli; Flávio de Mattos Oliveira; Luiz Carlos Severo
Journal:  Rev Soc Bras Med Trop       Date:  2013 May-Jun       Impact factor: 1.581

6.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.

Authors:  J Heitman; N R Movva; M N Hall
Journal:  Science       Date:  1991-08-23       Impact factor: 47.728

7.  Rck1 and Rck2 MAPKAP kinases and the HOG pathway are required for oxidative stress resistance.

Authors:  Elizabeth Bilsland; Claes Molin; Swarna Swaminathan; Anna Ramne; Per Sunnerhagen
Journal:  Mol Microbiol       Date:  2004-09       Impact factor: 3.501

8.  Role of Ca2+/calmodulin signaling pathway on morphological development of Candida albicans.

Authors:  Tatsuki Sato; Yukihiro Ueno; Toshihiko Watanabe; Takeshi Mikami; Tatsuji Matsumoto
Journal:  Biol Pharm Bull       Date:  2004-08       Impact factor: 2.233

9.  Inhibitors of the glyoxylate cycle enzyme ICL1 in Candida albicans for potential use as antifungal agents.

Authors:  Hong-Leong Cheah; Vuanghao Lim; Doblin Sandai
Journal:  PLoS One       Date:  2014-04-29       Impact factor: 3.240

Review 10.  New insights into innate immune control of systemic candidiasis.

Authors:  Michail S Lionakis
Journal:  Med Mycol       Date:  2014-07-14       Impact factor: 4.076

View more
  18 in total

Review 1.  The Future of Antifungal Drug Therapy: Novel Compounds and Targets.

Authors:  Caroline Mota Fernandes; Deveney Dasilva; Krupanandan Haranahalli; J Brian McCarthy; John Mallamo; Iwao Ojima; Maurizio Del Poeta
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Repurposing benzbromarone as antifolate to develop novel antifungal therapy for Candida albicans.

Authors:  Somdutt Mujwar; Avanish Tripathi
Journal:  J Mol Model       Date:  2022-06-18       Impact factor: 2.172

3.  Synergistic Antibiofilm Effects of Pseudolaric Acid A Combined with Fluconazole against Candida albicans via Inhibition of Adhesion and Yeast-To-Hypha Transition.

Authors:  Bin Zhu; Zhen Li; Hongmei Yin; Jun Hu; Yingjun Xue; Guanyi Zhang; Xin Zheng; Weiqin Chen; Xiaobo Hu
Journal:  Microbiol Spectr       Date:  2022-03-17

Review 4.  Fungal KATs/KDACs: A New Highway to Better Antifungal Drugs?

Authors:  Karl Kuchler; Sabrina Jenull; Raju Shivarathri; Neeraj Chauhan
Journal:  PLoS Pathog       Date:  2016-11-10       Impact factor: 6.823

Review 5.  Potential Antifungal Targets against a Candida Biofilm Based on an Enzyme in the Arachidonic Acid Cascade-A Review.

Authors:  Xinning Liu; Decai Wang; Cuixiang Yu; Tao Li; Jianqiao Liu; Shujuan Sun
Journal:  Front Microbiol       Date:  2016-12-06       Impact factor: 5.640

6.  Synergistic Effects and Mechanisms of Budesonide in Combination with Fluconazole against Resistant Candida albicans.

Authors:  Xiuyun Li; Cuixiang Yu; Xin Huang; Shujuan Sun
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

7.  Encapsulation of Antifungals in Micelles Protects Candida albicans during Gall-Bladder Infection.

Authors:  Shih-Hung Hsieh; Sascha Brunke; Matthias Brock
Journal:  Front Microbiol       Date:  2017-02-01       Impact factor: 5.640

Review 8.  Amino Acid Metabolism and Transport Mechanisms as Potential Antifungal Targets.

Authors:  Matthew W McCarthy; Thomas J Walsh
Journal:  Int J Mol Sci       Date:  2018-03-19       Impact factor: 5.923

9.  A New Series of Pyrrole-Based Chalcones: Synthesis and Evaluation of Antimicrobial Activity, Cytotoxicity, and Genotoxicity.

Authors:  Ahmet Özdemir; Mehlika Dilek Altıntop; Belgin Sever; Hülya Karaca Gençer; Handan Açelya Kapkaç; Özlem Atlı; Merve Baysal
Journal:  Molecules       Date:  2017-11-30       Impact factor: 4.411

10.  Antifungal Susceptibility and Biofilm Production of Candida spp. Isolated from Clinical Samples.

Authors:  Munmun B Marak; Biranthabail Dhanashree
Journal:  Int J Microbiol       Date:  2018-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.